Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human RENIN Protein, His Tag, 100µg  

Recombinant human RENIN Protein, His Tag, 100µg

Recombinant Human RENIN Protein (rhRenin) Leu24 -Arg406, produced in human 293 cells (HEK293), His Tag

Synonym
Recombinant Human Protein, REN, FLJ10761, Renin, angiotensinogenase

More details

REN-H5221-100

Availability: within 7 days

348,00 €

Background
Renin, also known as REN and angiotensinogenase, is a circulating enzyme that participates in the body\'s renin-angiotensin system (RAS), and plays an essential role in the elevation of arterial blood pressure and increased sodium retention by the kidney. Renin activates the renin-angiotensin system by cleaving angiotensinogen, produced by the liver, to yield angiotensin I, which is further converted into angiotensin II by ACE, the angiotensin-converting enzyme primarily within the capillaries of the lungs. Renin is secreted from kidney cells, which are activated via signaling from the macula densa, which responds to the rate of fluid flow through the distal tubule, by decreases in renal perfusion pressure (through stretch receptors in the vascular wall), and by sympathetic nervous stimulation, mainly through beta-1 receptor activation. Renin can bind to ATP6AP2, which results in a fourfold increase in the conversion of angiotensinogen to angiotensin I over that shown by soluble renin. In addition, renin binding results in phosphorylation of serine and tyrosine residues of ATP6AP2.[1] The level of renin mRNA appears to be modulated by the binding of HADHB, HuR and CP1 to a regulatory region in the 3\' UTR.[2] An over-active renin-angiotension system leads to vasoconstriction and retention of sodium and water. These effects lead to hypertension. Therefore, renin inhibitors can be used for the treatment of hypertension.[3]

Source
Recombinant Human RENIN, His Tag (REN-H5221) is expressed from human 293 cells (HEK293). It contains AA Leu 24 - Arg 406 (Accession # P00797-1).
Predicted N-terminus: Leu 24

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 43.1 kDa. The protein migrates as 46-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg of the rhRenin by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
N/A

Clinical and Translational Updates

(1) "Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers"
Alabsi, Acosta, Al-Obeidi et al
Pharmaceutics (2021) 13 (8)
(2) "Gene Polymorphisms of the Renin-Angiotensin System and Bleeding Complications of Warfarin: Genetic-Based Machine Learning Models"
Kim, Yee, Chang et al
Pharmaceuticals (Basel) (2021) 14 (8)
(3) "Angiotensin-Converting Enzyme 2 (ACE2) in the Context of Respiratory Diseases and Its Importance in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection"
Ambrocio-Ortiz, Pérez-Rubio, Del Ángel-Pablo et al
Pharmaceuticals (Basel) (2021) 14 (8)
Showing 1-3 of 65897 papers.
Please refer to product data sheet.